2438-57-5

Usage

Uses

Used in Pharmaceutical Industry:
(2S,4S)-4-FLUORO-PYRROLIDINE-2-CARBOXYLIC ACID is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique stereochemistry and fluorination contribute to the development of novel drugs with improved potency, selectivity, and pharmacokinetic properties.
Used in Chemical Research:
(2S,4S)-4-FLUORO-PYRROLIDINE-2-CARBOXYLIC ACID is used as a research compound for studying stereoelectronic effects on collagen stability. The compound's structural similarity to proline allows researchers to investigate the influence of fluorination on the conformation and stability of collagen, which is crucial for understanding the molecular basis of various diseases and developing targeted therapeutic strategies.
Used in Material Science:
(2S,4S)-4-FLUORO-PYRROLIDINE-2-CARBOXYLIC ACID can be used as a building block for the development of novel materials with specific properties, such as improved mechanical strength, thermal stability, or chemical resistance. The fluorinated pyrrolidine moiety can be incorporated into polymers, coatings, or other materials to enhance their performance in various applications.

InChI:InChI=1/C5H8FNO2/c6-3-1-4(5(8)9)7-2-3/h3-4,7H,1-2H2,(H,8,9)

Upstream product

• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 203866-18-6 methyl (2S,4R)-N-(tert-butyloxy)carbonyl-4-fluoropyrrolidine-2-carboxylate 
• 129430-93-9 (2S,4S)-methyl 4-hydroxy-1-tritylpyrrolidine-2-carboxylate 
• 129430-93-9 methyl (2S,4R)-4-hydroxy-1-tritylpyrrolidine-2-carboxylate 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 618-27-9 hydroxy L-proline 
• 203866-14-2 (2S,4R)-1-[(tert-butoxy)carbonyl]-4-fluoropyrrolidine-2-carboxylic acid 
• 132651-95-7 Methyl 1-acetyl-4-fluoro-D-prolinate 
• 203866-16-4 1-tert-butyl 2-methyl (2S,4S)-4-fluoropyrrolidine-1,2-dicarboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 231282-75-0 (6R,7aS)-6-hydroxy-3,3-bis(trifluoromethyl)tetrahydro-pyrrolo[1,2-c]oxazol-1-one 
• 51-35-4 4R-4-hydroxyproline 
• 203866-13-1 (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid 
• 132651-99-1 methyl 1-acetyl-cis-4-fluoro-L-pyrrolidin-5-one-2-carboxylate 

Downstream Products

• 203866-19-7 (2S,4S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-fluoropyrrolidine-2-carboxylic acid 
• 587888-04-8 N-tert-butoxycarbonyl-(2S,4S)-4-fluoroproline benzyl ester 
• 203866-20-0 (2S,4R)-N-Fmoc-4-fluoroproline 
• 1443240-81-0 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((2S,4R)-4-fluoro-1-methyl-pyrrolidin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 
• 1007878-14-9 (2S,4R)-N-methyl-4-fluoropyrrolidine-2-carboxylic acid hydrochloride 
• 4347-18-6 4-oxo-L-proline 
• 1612854-12-2 C₅₃H₆₂F₂N₈O₇ 
• 1612854-09-7 C₁₉H₂₄BrFN₄O₅ 
• 79108-50-2 1-Nitroso-cis-4-fluoro-L-proline 

Relevant academic research and scientific papers

HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE

This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular,the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

Fluorous synthesis of 18F radiotracers with the [ 18F]fluoride ion: Nucleophilic fluorination as the detagging process

Tag team: The flouro-detagging of flourous sulfonates by the [ 18F]fluoride ion was found to be an advantageous strategy for the preparation of various 18F-labeled prosthetic groups and known radiotracers (see picture). Fluorous solid phase extraction (FSPE) was used to separate the excess fluorous precursor from the labeled material, which suggests that traditional purification protocols such as distillation or tedious separation can be avoided. (Chemical Equation Presented).

Synthesis of n.c.a. cis- and trans-4-[18F]fluoro-L-proline, radiotracers for PET-investigation of disordered matrix protein synthesis

A radiosynthesis of n.c.a. (2S,4R)-4-[18F]fluoroproline (trans-configuration) and its diastereomer (2S,4S)-4-[18F]fluoroproline (cis-configuration) has been developed. It allows the routine production of up to 18 GBq of product for c

Practical synthesis of Boc and Fmoc protected 4-fluoro and 4-difluoroprolines from trans-4-hydroxyproline

Boc-cis-4-fluoro-L-proline and 4-difluoro-L-proline, usable in classical peptide synthesis, were obtained in respectively 71% (3 steps) and 65% (4 steps) overall yields from the readily available trans-4-hydroxy-L-proline methyl ester. The corresponding fluorinated trans-isomer was isolated in 24% yield (5 steps). Transformation of Boc-protected compounds to their Fmoc-equivalents was performed in high yields.

Synthesis of (2S)-4,4-difluoroproline, (2S,4R)-4-fluoroproline and their derivatives from (S)-aspartic acid

Syntheses for (2S)-4,4-difluoroproline, (2S,4R)-4-fluoroproline and their derivatives are described starting from (S)-aspartic acid, using hexafluoroacetone as the protecting reagent and DAST as the fluorinating agent.

Stereospecific syntheses of all four stereoisomers of 4-fluoroglutamic acid

(+)-L-threo-4-fluoroglutamic acid . (-)-D-threo-4-Fluoroglutamic acid was prepared analogously from trans-4-hydroxy-D-proline, obtained from its diastereomer by inversion of configuration at carbon 4 of the pyrrolidine ring using the diethyl azodicarboxylate-triphenylphosphine procedure. cis-4-Hydroxy-L-proline, necessary for the synthesis of (+)-L-erythro-4-fluoroglutamic acid , was prepared from trans-4-hydroxy-L-proline by benzyloxycarbonylation at the nitrogen, oxidation of the 1-benzyloxycarbonyl-trans-4-hydroxy-L-proline to 1-benzyloxycarbonyl-4-oxo-L-proline, its reduction to 1-benzyloxycarbonyl-cis-4-hydroxy-L-proline and deprotection of the latter at the nitrogen. (-)-cis-4-Fluoro-L-proline and (+)-trans-4-fluoro-D-proline were isolated after the hydrolysis of incompletely oxidized methyl 1-acetyl-cis-4-fluoro-L-prolinate and methyl 1-acetyl-trans-4-fluoro-D-prolinate, respectively.